Kite Licenses Antibodies and Establishes Collaboration With Teneobio in Multiple Myeloma

/in /by

— Kite and Teneobio will Collaborate on Next-Generation Dual-Targeting CAR T Therapies in Multiple Myeloma Utilizing UniAb® Antibodies —

April 02, 2020 08:30 AM Eastern Daylight Time

SANTA MONICA, Calif. & NEWARK, Calif.–(BUSINESS WIRE)–Kite, a Gilead Company (Nasdaq: GILD), and Teneobio, Inc. announced the companies have entered into a license and collaboration agreement through which Kite will receive exclusive rights to certain antibodies directed to B-cell maturation antigen (BCMA).

Read more

Teneobio’s Lead Candidate, TNB-383B, Receives Orphan Drug Designation from the FDA for the Treatment of Multiple Myeloma

/in /by

NEWARK, Calif., Nov. 06, 2019 (GLOBE NEWSWIRE) — Teneobio, Inc., a clinical-stage biotechnology company developing engineered bispecific antibodies for the treatment of cancer announced today that it has received orphan drug designation by the U.S. Food and Drug Administration (FDA) for the treatment of multiple myeloma.
Read more

Teneobio and Selexis Expand Relationship with Three Commercial License Agreements for Multi-specific Antibody Candidates in Oncology

/in /by

GENEVA & NEWARK, Calif.–(BUSINESS WIRE)–Selexis SA and Teneobio, Inc. announced today that they have signed three commercial license agreements (CLAs) for the development of Teneobio’s Human Heavy-Chain Antibodies (UniAbs®), a new class of multi-specific biologics, for the treatment of multiple myeloma, lymphoma and prostate cancer. The CLAs expand the companies’ previously established relationship, including a service agreement signed between Teneobio and Selexis in December 2018.
Read more

Teneobio Licenses Oncology Multispecific Product to Janssen

/in /by

NEWARK, Calif., Sept. 30, 2019 (GLOBE NEWSWIRE) — Teneobio, Inc., a clinical-stage biotechnology company developing engineered bispecific antibodies for the treatment of cancer announced today that as a result of its work with scientists from Janssen Research & Development, LLC, Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, has elected to exercise a commercial option to license and advance an undisclosed multispecific product for development in an oncology indication.
Read more

Teneobio Doses First Patient in Phase 1 Study of TNB-383B for the Treatment of Patients with Multiple Myeloma

/in /by

NEWARK, Calif., July 15, 2019 (GLOBE NEWSWIRE) — Teneobio, Inc. a clinical-stage biotechnology company developing engineered bispecific antibodies for the treatment of cancer announced today that the first patient has been dosed with TNB-383B in a Phase 1 clinical study to evaluate the safety and tolerability of its differentiated anti-BCMAxCD3, a bispecific antibody that redirects T-cells to kill multiple myeloma cells with minimal cytokine release.
Read more

Teneobio Announces US FDA Approval of the Investigational New Drug Application for TNB-383B and the Initiation of Phase I Clinical Studies in Multiple Myeloma Patients

/in /by

NEWARK, Calif., April 29, 2019 (GLOBE NEWSWIRE) — Teneobio, Inc. and its affiliate TeneoOne, Inc. announced today that their investigational new drug application (IND) for TNB-383B, a bispecific T-cell engaging antibody for the treatment of multiple myeloma, was cleared for the initiation of Phase I clinical studies by the US Food and Drug Administration (FDA) on April 24th, 2019. The ongoing development of TNB-383B is being pursued in collaboration with AbbVie, Inc.
Read more

AbbVie and Teneobio Announce a Strategic Transaction to Develop a New Treatment for Multiple Myeloma

/in /by

NORTH CHICAGO, Ill. and MENLO PARK, Calif., Feb. 11, 2019 /PRNewswire/ — AbbVie (NYSE: ABBV), Teneobio, Inc. and its affiliate TeneoOne, Inc. announced today that they have entered a global strategic transaction to develop and commercialize TNB-383B, a BCMA-targeting immunotherapeutic for the potential treatment of multiple myeloma.
Read more